Although significant advances in hemophilia treatment have improved patient outcomes and
quality of life, one of the greatest complications in severe hemophilia A is the development of …

Hemophilia A (HA) is an X-linked hereditary bleeding disorder caused by deficiency of
coagulation factor (F) VIII activity. One of the greatest complications in the treatment of HA is …

Inhibitor formation is a serious complication of factor VIII (FVIII) replacement therapy for the X‐
linked bleeding disorder haemophilia A and occurs in 20%–30% of patients. No prophylactic …

Inhibitors of factor VIII (FVIII) remain the most challenging complication of FVIII protein
replacement therapy in hemophilia A (HA). Understanding the mechanisms that guide FVIII …

Emicizumab is a bispecific monoclonal antibody that substitutes for the function of missing or
deficient factor VIII (FVIII) in people with hemophilia A (PwHA). Long-term safety and efficacy …

Blood platelets have unique storage and delivery capabilities. Platelets play fundamental
roles in hemostasis, inflammatory reactions, and immune responses. Beyond their functions …

Emicizumab mimics the hemostatic activity of activated factor VIII (FVIIIa) within the tenase
complex. Despite functional similarities between FVIIIa and emicizumab, conventional …

Antecedentes: La hemofilia es una enfermedad de origen genético, recesiva y ligada al
cromosoma X; su principal manifestación clínica es la hemorragia, cuyo grado depende del …

Introduction Patients with hemophilia A treated with coagulation Factor VIII (FVIII) products
are at risk for developing anti‐FVIII antibodies. The ABIRISK Consortium aimed to provide …

The development of anti-drug antibodies represents a significant barrier to the utilization of
protein-based therapies for a wide variety of diseases. While the rate of antibody formation …